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Effect of vascular endothelial growth factor gene therapy on
post-traumatic peripheral nerve regeneration and
denervation-related muscle atrophy
S Moimas1,2,6, F Novati3,6, G Ronchi4,5, S Zacchigna1, F Fregnan4,5, L Zentilin1, G Papa3, M Giacca1,2, S Geuna4,5, I Perroteau4,
ZM Arnezˇ3 and S Raimondo4,5
Functional recovery after peripheral nerve injury depends on both improvement of nerve regeneration and prevention of
denervation-related skeletal muscle atrophy. To reach these goals, in this study we overexpressed vascular endothelial growth
factor (VEGF) by means of local gene transfer with adeno-associated virus (AAV). Local gene transfer in the regenerating peripheral
nerve was obtained by reconstructing a 1-cm-long rat median nerve defect using a vein segment filled with skeletal muscle fibers
that have been previously injected with either AAV2-VEGF or AAV2-LacZ, and the morphofunctional outcome of nerve regeneration
was assessed 3 months after surgery. Surprisingly, results showed that overexpression of VEGF in the muscle-vein-combined guide
led to a worse nerve regeneration in comparison with AAV-LacZ controls. Local gene transfer in the denervated muscle was
obtained by direct injection of either AAV2-VEGF or AAV2-LacZ in the flexor digitorum sublimis muscle after median nerve
transection and results showed a significantly lower progression of muscle atrophy in AAV2-VEGF-treated muscles in comparison
with muscles treated with AAV2-LacZ. Altogether, our results suggest that local delivery of VEGF by AAV2-VEGF-injected
transplanted muscle fibers do not represent a rational approach to promote axonal regeneration along a venous nerve guide. By
contrast, AAV2-VEGF direct local injection in denervated skeletal muscle significantly attenuates denervation-related atrophy, thus
representing a promising strategy for improving the outcome of post-traumatic neuromuscular recovery after nerve injury and
repair.
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INTRODUCTION
Gene therapy is an emerging issue in tissue engineering of
damaged organs including those belonging to the neuromuscular
system.1,2 One of the potential applications of gene therapy is
represented by the treatment of traumatic nerve injuries. In fact,
following nerve damage, axon continuity is interrupted and the
distal axonal tract goes toward degeneration.3 As a consequence,
the anatomical and functional connections between motoneurons
and skeletal muscle fibers are lost inducing a progressive muscle
atrophy.4,5 If nerve continuity is guaranteed (by surgical repair),
the proximal stump of damaged axons can regenerate within the
distal nerve stump, reach the denervated muscle and restore
functional connection with it.3
As muscle atrophy is accompanied by a progressive loss-of-
function recovery after reinnervation,6–8 the lapse of time
between the traumatic event and the restoration of the
neuromuscular function is one of the key factors for the
eventual functional recovery. For this reason, improvement of
motor function recovery after traumatic nerve injury and repair
can be obtained by both accelerating axonal regeneration, thus
reducing the denervation time lapse, and decelerating the
progression of skeletal muscle atrophy, thus improving its
capacity to restore function when regenerated axons eventually
reach it.
Gene therapy based on adeno-associated virus (AAV) appear to
be a rational approach to reach this goal as AAVs have already
been used to efficiently deliver therapeutic genes to muscle and
nerve, and to induce muscle/neural protection and repair in
different experimental models.1,9–13
Various genes are candidates for promoting peripheral axon
regeneration14 and preventing muscle atrophy, including
VEGF.13,15–19 Haninec et al.16 demonstrated that increasing VEGF
protein in nerve stumps resulted in a higher quality of axon
regeneration and functional reinnervation after both end-to-end
and end-to-side neurorrhaphy. In particular, VEGF was shown to
promote axonal outgrowth and Schwann cell proliferation.16
Moreover, Sondell et al.17 reported that VEGF was able to
stimulate Schwann cell invasion and neovascularization after a
sciatic nerve transection. Yet, several studies highlighted that
VEGF interacts with satellite cells of skeletal muscle and promotes
its regeneration after trauma.13,18,20 Moreover, VEGF was shown
to have an antiapoptotic and a direct myogenic effect,13 and to be
able to enhance muscle force restoration and reduced the amount
of connective tissue after traumatic injury.18
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Therefore, we wondered whether VEGF overexpression may
exert a positive effect on both post-traumatic axonal regeneration
and denervation-related muscle atrophy in a rat upper limb
model.21
RESULTS
Evaluation of AAV muscle transduction
In Figure 1 results of the pilot study performed to evaluate the
efficiency of AAV muscle infection are reported. Viral DNA
persistence (Figures 1a and c) and transgene expression
(Figures 1b and d) were analyzed in the two models used in this
study: (i) peripheral nerve regeneration and (ii) skeletal muscle
atrophy.
In the model of peripheral nerve regeneration, AAVs were
injected in the pectoralis major muscle 14 days before main
surgery in order to allow proper transgene expression. The area of
injection was marked by two suture stitches and, to confirm the
identification of the transduced muscle for the generation of the
muscle-in-vein (MIV) conduit, we assessed both vector persistence
and transgene expression in a portion of muscle withdrawn from
the area of injection but not used for the conduit. We evaluated
also the presence of the viral DNA and the expression of the
transgene in the MIV conduit withdrawn 14 days after surgery.
Viral genomes were found in the MIV conduit (Figure 1a) and the
expression of the transgene was detectable (Figure 1b), even if a
decrease was observed for both parameters. The reduction in the
number of viral genomes might be explained both by the loss of
nonnuclear DNA, as previously reported,22 or by the lowering in
the number of healthy muscle fibers inside the MIV conduit, as
described in the following paragraphs. Concerning the reduction
in transgene expression, it might be due to the loss of muscle fiber
within the conduits, as already mentioned.
In the second experimental model, AAV injection and muscle
denervation were performed at the same time. We evaluated the
viral persistence as well as the transgene expression at the
moment of tissue withdrawal, and we were able to detect the
presence of viral DNA as well as the expression of the transgenes
in the transduced flexor digitorum sublimis muscles, 14 days after
injection. As reported in Figures 1c and d, AAVs were found to
persist in the injected muscle and transgene expression was also
detected.
Peripheral nerve regeneration
Functional recovery and stereological analysis results are shown in
Figure 2.
Three months after nerve surgery all animals underwent
functional assessment by grasping test, and rats belonging to
the MIV-VEGF group showed a significant worse functional
recovery than MIV-LacZ rats (Figure 2a). Stereological results
showed that the MIV-VEGF group had significantly less fibers
(Figure 2b) that were significantly bigger than controls (Figure 2c),
whereas the myelin thickness was similar in the two groups
(Figure 2c).
Morphological observation provided an explanation of the
functional and stereological results. Light microscopy (Figures 3a–
d) showed that the worse functional recovery and the lower
number of fibers in the MIV-VEGF group was justified by the fact
that muscle fibers were still abundant in the graft (Figures 3a and
b), whereas in control (MIV-LacZ) group less muscle fibers were
detected (Figures 3c and d). By electron microscopy analysis,
muscle fibers in the graft of MIV-VEGF showed a reduced atrophy
(Figures 3e and f) in comparison with control samples (Figures 3g
and h). Indeed, in MIV-VEGF group several myotubes, not detected
in controls, could be observed inside the graft (Figure 3e).
Moreover, sarcomeres were still well organized and mitochondria
were still intact (Figure 3f). In MIV-LacZ, muscle fibers were absent
(Figures 3c and d) or had evident sign of vacuolization, sarcomeric
disorganization and destroyed mitochondria (Figures 3g and h). In
MIV-VEGF, there was also a higher number of blood vessels in
comparison with MIV-LacZ (data not shown).
Moreover, gene expression analysis of genes involved in the
apoptotic process, such as Bcl2l11, Bmf and Bad, showed that in
the MIV-VEGF samples the levels of pro-apoptotic genes were
reduced, suggesting an antiapoptotic role of VEGF on muscle
fibers13,23 (Supplementary Figure 1).
Prevention of muscle atrophy
One month after denervation and treatment with AAV2-VEGF, the
denervated muscles had a significantly higher weight
(121±11mg) than muscles treated with AAV2-LacZ (96±5mg).
Figure 1. Histograms showing viral DNA as well as transgene
expression in the injected tissues. Peripheral nerve regeneration
model (a and b; number of rats analyzed¼ 16): quantification of viral
DNA in the pectoralis major muscle used to fill the MIV conduit at
the moment of surgery and in the MIV conduits 14 days after
surgery, quantified by real-time PCR (a); transgene relative expres-
sion quantification in the pectoralis major muscle used to fill the MIV
conduit at the moment of surgery and in the MIV conduits 14 days
after surgery; results are expressed after normalization over the
levels of the housekeeping gene GAPDH (b). Skeletal muscle atrophy
model (c and d; number of rats analyzed¼ 8): quantification of viral
DNA in the flexor digitorum sublimis muscle withdrawn 14 days
after denervation and infection, quantified by real-time PCR (c);
transgene relative expression quantification in the flexor digitorum
sublimis muscle withdrawn 14 days after denervation and infection;
results are expressed after normalization over the levels of the
housekeeping gene GAPDH (d).
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Light microscopy on semithin sections stained with toluidine
blue of normal muscle (Figure 4a) and denervated muscle 1
month after treatment with AAV2-LacZ (Figure 4b) or AAV2-
VEGF (Figure 4c) showed that muscles treated with AAV2-VEGF
had a reduced atrophy in comparison with denervated muscles
treated with AAV2-LacZ. In fact, muscle fibers treated with AAV2-
LacZ were smaller than AAV2-VEGF and had evident signs
of sarcomeric disorganization with a greater amount of connec-
tive tissue (Figure 4b). The different size of muscle fibers was
also confirmed by statistical analysis of stereologogical data
(Figure 4d).
In addition to the observed effect of VEGF on fiber size, we also
showed a preferential protective effect of VEGF on skeletal fast
fibers. Immunofluorescence analysis of muscle sections showed
that VEGF overexpression had almost no effect on slow fiber cross-
sectional area, whereas the fast fiber cross-sectional area was
significantly increased compared with the denervated muscle
treated with AAV-LacZ (29%±5% vs 44%±7%, AAV-LacZ
and AAV-VEGF, respectively). Representative images and fiber
cross-sectional area quantification are reported in Figures 5a and
b, respectively.
DISCUSSION
Whereas a large body of research has been carried out over the
last 20 years for improving post-traumatic peripheral nerve
regeneration, the clinical outcome of nerve reconstruction is
often still unsatisfactory.24–26 In a clinical setting of peripheral
nerve damage, both nerve and muscles undergo a degeneration
process and the identification of molecules able to foster nerve
regeneration as well as to protect skeletal muscle from atrophy is
thus required. As VEGF is known to promote axonal regeneration
and protect muscle fibers from degeneration,19,27 the present
study was aimed at exploring the possibility to effectively use a
local gene therapy approach aimed to overexpress VEGF in order
to improve functional recovery after peripheral repair.
VEGF is a growth factor that has been used in various animal
models of neurodegeneration and the findings are not always
clear-cut. The outcome in each study may depend on the variables
of that particular study, for example, lesion model, concentration
of VEGF used, route-of-delivery and so on. To be successful with
VEGF therapy is important to consider all these parameters.
Owing to relatively short (B30–45min) half-life of VEGF,28 a
carrier is needed to release VEGF in a controlled fashion in order to
obtain a sustained effect. Therefore, we used AAV-VEGF gene
therapy that is an efficient and stable gene transfer method to
bypass this limitation. The features of the AAV life cycle, including
its defectiveness and ability to persist in transduced cells as a
latent viral episome, suggested early on that this virus appears
to be an excellent tool for in vivo gene transfer. Over the last
few years, AAVs have gained increasing popularity because of
the high efficiency of transduction of post-mitotic tissues such as
muscle.9,29,30 The main goals of our study were twofold: to foster
axonal regeneration along muscle-vein-combined conduits31,32
used to bridge a 1-cm-long rat median nerve gap and to
prevent denervation-related atrophy of fingers flexor muscle
after complete rat median nerve transection.21 The muscle-vein-
combined conduit was chosen in our study to repair injured nerve
because of the high efficiency of muscle infection with AAV, and
thus it seemed to be a good method for VEGF local delivery.
Results can be summarized as follows: (i) AAV2-VEGF injection
succeeded in gene transfer into muscle tissue, (ii) in both
experimental models, local VEGF delivery prevented muscle
atrophy progression; (iii) whereas muscle atrophy prevention
represents a positive prognostic factor for neuromuscular
recovery, local VEGF delivery inside the muscle-vein-combined
conduit resulted in a significantly reduced functional recovery in
comparison with controls.
These observations confirm that skeletal muscle is a good
means for AAV-mediated local delivery of secreted molecules,29 as
already shown in preclinical studies and clinical trials for treatment
of hemophilia B.33–35 Indeed, clinical trials have already been
concluded and showed good results on restoration of protein
levels as reviewed in study by Buning36 and Giacca.36,37 Gene
therapy with AAVs has been growing in the last years and many
serotypes have been identified for the transduction of post-mitotic
tissues such as skeletal muscles, hearts, neurons and retina.38,39
Among the serotype that are reported to be able to transduce
skeletal muscles, in previous works from our laboratory,39
we showed that serotype 2 displays good transduction efficiency
when directly injected into the skeletal muscle;12,13,39–41 indeed, we
choose this serotype to study the effect of VEGF overexpression in
our animal models of nerve regeneration and muscle atrophy.
In this study, AAVs were injected in the pectoralis major muscle
and, to confirm transduction efficiency and transgene expression,
we quantified the number of viral genomes and the expression
levels both at the moment of muscle withdrawal and 14 days after
Figure 2. Histograms showing the results of functional recovery
evaluated by grasping test (a) and the results of morphometrical
evaluation of nerve regeneration, (b) number of myelinated fiber in
the distal part of the median nerve, (c) axon and fibers diameter and
myelin thickness in MIV-LacZ and MIV-VEGF groups (number of rats
analyzed¼ 14). *Pp0.05; **Pp0.01.
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main surgery. We showed, in agreement with our previous data,39
that we were able to transduce the muscle and that transgene
expression was detectable also within the MIV conduit. The
presence of transgene expression was also analyzed by histology
and transduced fibers were detected (data not shown).
As far as target muscles are concerned, we observed the
occurrence of denervation-related muscle atrophy in both
experimental models as expected. We investigated muscle
atrophy after 1 month of denervation because it has been
shown that this post-denervation time point is sufficient to induce
Figure 3. Toluidine blue-stained semithin sections observed in light microscopy (a–d) and electron microscopy (e–h) images of MIV-LacZ (c, d,
g, h) and MIV-VEGF (a, b, e, f ) conduits 3 months after surgery. In MIV-VEGF there are a lot of muscle fibers still in the conduit that have well-
organized sarcomeres and intact mitochondria. Some myotube with central nucleus are also detectable inside the MIV-VEGF conduit (arrow).
In MIV-LacZ conduit the very few muscle fibers that can be observed have different sign of atrophy, such as sarcomeric disorganization,
vacuolization and mitochondria destruction. Scale bars: (a and c): 50 mm; (b and d): 20 mm; (e and g):5 mm; (f and h):1 mm.
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severe fiber atrophy in rat flexor digitorum sublimis muscle.42
However, the degree of denervation-related muscle atrophy was
significantly lower in AAV-VEGF-treated muscles, suggesting
that local delivery of AAV-VEGF in denervated muscle should be
seen as a rational strategy for limiting atrophy progression,
and thus eventually improving functional recovery after nerve
reconstruction.
During skeletal muscle atrophy the ubiquitin-proteasome
system is a key player, and a connection among VEGF and the
proteasome has already been published.43,44 Therefore, the VEGF
protective role that we observed might be due to an inhibition of
the ubiquitin-proteasome. Another possible explanation relies on
the reported protective role of insulin-like growth factor-1, which
is able to protect skeletal muscle cells from atrophy via activation
of the PI3K–Akt pathway.45 VEGF, by interacting with VEGFR2,
signals through the PI3K–Akt pathway, thus suggesting that VEGF
might protect from atrophy by the same pathway. The role of this
pathway in muscle atrophy is suggested also by the observation
that depletion of TRAF6 in skeletal muscle cells, which is
able to induce Akt ubiquitination, preserve muscle fibers from
Figure 4. Light microscopy of toluidine blue-stained semithin sections of a normal muscle (a) and denervated muscle 1 month after surgery
and treatment with AAV-LacZ (b) or AAV-VEGF (c). Histogram in d shows the results of morphometrical evaluation of muscle fibers size
(number of rats analyzed¼ 17). #Pp0.05 VEGF vs LacZ; **Pp0.01 VEGF and LacZ vs control (CTRL). Scale bars: 25 mm.
Figure 5. Muscle sections were stained in immunohistochemistry with laminin (red) and slow myosin (green) in order to study the effect of
VEGF overexpression on skeletal muscle fiber cross-sectional area. Cellular nuclei were counterstained with 4’,6-diamidino-2-phenylindole
(DAPI; blue). Scale bars: 25 mm (a). Histograms that represent quantification of the fiber cross-sectional area (b); results are expressed as a
percentage compared with the matched fiber type in the contralateral healthy muscle (number of rats analyzed¼ 6). *Pp0.05 VEGF vs LacZ.
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degradation upon denervation.46 Further studies are required to
address this point.
VEGF treatment, alone or in combination with other anti-
atrophic treatments such as physiotherapy, might be particularly
useful in case of proximally located nerve lesions owing to the
long time required by regenerating axons for reaching the
denervated muscles.47
On the other hand, as far as improvement of axonal
regeneration is concerned, our results showed that VEGF-related
anti-atrophic effects on the muscle fiber used as a means for AAV-
mediated delivery to regenerating axons made this gene transfer
strategy not suitable for this specific application, as reduced
muscle atrophy concurrently decreased the number of regenerat-
ing axons inside the nerve guide and led to a significant lower
functional recovery of the motor function. The failure of the axons
regeneration can be explained also with the fact that muscle fibers
in the conduit might mimic their original end target (the flexor
digitorum sublimes muscle), and therefore be reinnervated by
sprouting axons.
Future studies need to go on along two directions. First,
alternative means for the delivery of VEGF inside nerve guides
should be sought to improve both number and size of
regenerating axons. Second, the exploration of alternative
molecules to be delivered by AAV-mediated gene transfer inside
muscle-vein-combined nerve conduits. In the latter case, it will be
important to select genes that code for molecules that do not
exert anti-atrophic effect on skeletal muscle fibers.
MATERIALS AND METHODS
Experimental design
For this study, we used a total number of 56 adult Wistar rats (weight 250–
300 g).
A pilot study was performed in order to evaluate the efficiency of muscle
transduction by AAVs. Pectoralis major muscle, then used for the
peripheral nerve regeneration study, was injected with AAV2-LacZ or with
AAV2-VEGF (four animals per group) and analyzed at the moment of
surgery and in the MIV conduits 14 days after surgery. Flexor digitorum
sublimis muscle, then used for the study of muscle atrophy, was injected
with AAV2-LacZ or with AAV2-VEGF (four animals per group). Injected
muscles were analyzed to demonstrate either b-galactosidase or VEGF
expression 14 days after injection.
After the preliminary study, the effect of VEGF overexpression on
peripheral nerve regeneration was studied in a first experimental group.
The median nerve of adult Wistar rats was cut and repaired with a graft
constituted by a vein filled with muscle fibers (MIV) of the pectoralis major
previously transduced with either AAV2-VEGF (MIV-VEGF) or AAV2-LacZ
(MIV-LacZ, as control; seven animals per group). Functional recovery was
assessed by grasping test 3 months after surgery. Regenerated nerves (MIV
conduits) were withdrawn 3 months after surgery and analyzed with
morphological and stereological techniques.
A second experimental group was used to study the prevention of
muscle atrophy evaluating the effect of VEGF overexpression on
denervated muscles. The median nerve of adult rats Wistar was transected
and the flexor digitorum sublimis muscle was injected with either AAV2-
VEGF or AAV2-LacZ (six animals per group). Five rats did not undergo
surgery, and the normal flexor digitorum sublimis muscles were withdrawn
and used as controls. Transduced muscles were collected 1 month after
surgery and analyzed with morphological and stereological techniques.
Recombinant AAV production
The recombinant AAV vectors used in this study were produced by the
AAV Vector Unit at ICGEB Trieste (http://www.icgeb.org/avu-core-
facility.html), according to the protocol previously described.12,13,41 All
the vectors used in this study express the various complementary DNAs
under investigation (hVEGF-A165, b-galactosidase) under the control of the
constitutive cytomegalovirus immediate early promoter. All the viral stocks
used in this study had a titerX1 1012 viral genome particles per ml. The
proper expression of all transgenes was tested in vitro by western blotting
using specific antibodies after transduction of HT1080 cells and in vivo by
real-time PCR quantification of the transgene messenger RNAs in
transduced tissues.
Surgical procedure
All animals were housed in a temperature- and humidity-controlled room
with 12–12 h light/dark cycles, and were fed with standard chow and water
ad libitum. Adequate measures were taken to minimize pain and
discomfort taking into account human end points for animal suffering
and distress. All surgeries were performed with the approval of the local
Institution’s Animal Care and Ethics Committee and in accordance with the
European Communities Council Directive of 24 November 1986 (86/609/
EEC). The animals were operated under deep anesthesia by tiletamine-
zolazepam (zoletil) intramuscularly (3mg kg 1) with the aid of an
operating microscope (Zeiss OPMI 7, Milano, Italy).
AAV injection. The muscle, pectoralis major or flexor digitorum sublimes
of the forelimb, was exposed and injected with either AAV2-LacZ or AAV2-
VEGF (three injections of 20ml corresponding to 1 1011 viral genome
particles per rat). In the model of peripheral nerve regeneration, the area of
injection in the pectoralis major muscle was marked by two suture stitches
in order to allow its identification at the moment of the main surgery.
Median nerve injury and repair. The median nerve of the left forelimb was
approached from the axillary region to the elbow with a longitudinal skin
approach and, under operative microscope, was carefully exposed and cut.
Transected median nerve was immediately repaired by means of a 10-mm-
long graft made by MIV-combined nerve guide. This conduit was
constituted by the epigastric vein filled with pectoral muscle fibers
transduced by either AAV2-LacZ or AAV2-VEGF.
The muscle fibers of the pectoral muscle were withdrawn and put in the
vein longitudinally, so that the basal lamina of myotubes were aligned
throughout the length of conduit.48
The graft was sutured using three or four stitches of 9–0 monofilament
nylon for each stump.31
In order to prevent interferences with the grasping test, the contralateral
median nerve was transected at the middle third of the brachium and its
proximal stump was sutured in the pectoralis major muscle to avoid
spontaneous reinnervation.49
A 15-mm-long segment of the repaired median nerve (10mm of graft
and 5mm of distal nerve) was withdrawn 3 months after surgery.
Muscle denervation. Flexor digitorum sublimis muscles of the forelimb
were denervated by transection of a segment 10-mm-long of the median
nerve that, in the rat, is the only nerve controlling these muscles. Both
proximal and distal ends of the transected median nerves were twisted
and sutured to the fascia superficialis to avoid spontaneous axon
regeneration. At the time of surgery, flexor digitorum sublimis muscles
were transduced by either AAV2-LacZ or AAV2-VEGF, and harvested 1
month later.
Biomolecular analysis
Transduced muscles and MIV conduits were harvested and processed for
DNA/RNA extraction. In the peripheral nerve regeneration model, at the
moment of surgery, the section of injected muscle not used for the conduit
preparation was stored for further biomolecular analysis. DNA was
extracted using the DNeasy Blood and Tissue kit (Qiagen, Monza, Italy),
following manufacturer’s instructions. RNA was extracted by TriZol reagent
(Invitrogen, Monza, Italy), following manufacturer’s instruction, DNAse
treated and reverse transcribed using random primers. The presence of
viral DNA as well as the expression of the transgenes in the tissues were
evaluated by real-time PCR using TaqMan probe-based assays (Applied
Biosystems, Monza, Italy). The number of viral DNA molecules was
calculated on the basis of a standard curve generated from serial dilutions
of the pAAV-VEGF plasmid and normalized to DNA amount. For transgene
expression, the levels of hVEGF-A and b-galactosidase were normalized by
the levels of the housekeeping gene GAPDH.
For viral DNA detection, a cytomegalovirus promoter-specific custom
PCR assay was used (primer forward 50-TGGGCGGTAGGCGTGTA-30 , primer
reverse 50-CGATCTGACGGTTCACTAAACG-30 and probe FAM (6-carboxy-
fluorescein)-TGGGAGGTCTATATAAGC), whereas for transgene expression
the following TaqMan predeveloped assays were used: Hs00900055_m1
(hVEGF-A), Mr03987581_mr (LacZ) and Rn99999916_s1 (rat GAPDH). PCR
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reactions were performed in a CFX96 Real-Time System (Bio-Rad, Segrate,
Milano, Italy).
The complementary DNA was used as a template for real-time PCR
amplification to detect the expression levels of pro-apoptotic genes
(Bcl2l11, Bmf, Bad); the housekeeping gene GAPDH was used to normalize
the results. The following predeveloped assays (Applied Biosystems)
were used: Rn00674175_m1 (Bcl2l11), Rn00594968_m1 (Bmf) and
Rn00575519_m1 (Bad).
Grasping test
All animals with the median nerve repaired with the MIV were tested with
grasping test in order to evaluate the functional recovery 3 months after
surgery.
Grasping test was performed following the same procedure previously
described,49 using the BS-GRIP Grip Meter (2Biological Instruments, Varese,
Italy). This is a device constituted by a precision balance connected to a
grid that the rat can grip. The test is carried out by holding the rat by the
tail and putting it close enough to the device to grasp it. The rat is allowed
to pull on the bar until it loses the grip. The balance records the maximum
weight that the animal manages to hold up before losing the grip. Each
animal was tested three times and the average value was recorded.
Morphology and stereology
The repaired median nerve was removed (10mm of graft and 5mm of
distal nerve), fixed and prepared for qualitative analysis and quantitative
morphometry (stereology) of myelinated nerve fibers. Muscles followed
the same procedures.
Resin embedding. Nerve and muscle samples were fixed in 2.5%
glutaraldehyde, washed in Sorensen phosphate buffer 0.1 M (pH 7.4) with
1.5% saccarose and post-fixed in 2% osmium tetroxide for 2 h. After
dehydration in ethanol, samples were cleared in propylene oxide and
embedded in Glauerts’ embedding mixture of resins consisting in equal
parts of Araldite M and Araldite Harter, HY 964 (Merck, Darmstad,
Germany), containing 0.5% of the plasticizer dibutyl phthalate and 1–2% of
the accelerator 964, DY 064 (Merck).
Light microscopy and stereology. For high-resolution light microscopy,
2.5mm transversal cross-sections of the repaired median nerve and muscle
samples were obtained using an Ultracut UCT ultramicrotome (Leica
Microsystems, Wetzlar, Germany). Sections were stained by toluidine blue
and used for qualitative and quantitative morphological analysis that was
performed using a DM4000B microscope equipped with a DFC320 digital
camera and an IM50 image manager system (Leica Microsystems).
One semithin section from each nerve and from each muscle was
randomly selected and used for the quantitative analysis.
The total cross-sectional area of the nerve was measured and sampling
fields were then randomly selected using a protocol previously
described.50,51 Bias arising from the ‘edge effect’ was coped with the
employment of a two-dimensional disector procedure that is based on
sampling the ‘tops’ of fibers.52,53 Mean fiber density in each disector was
then calculated by dividing the number of nerve fibers counted by the
disector’s area (Nmm 2). Finally, total fiber number (N) in the nerve was
estimated by multiplying the mean fiber density by the total cross-sectional
area of the whole nerve. Two-dimensional disector probes were also used for
the unbiased selection of a representative sample of myelinated nerve fibers
for estimating circle-fitting diameter and myelin thickness.
The same stereological principles were used for muscle fibers’ cross-
sectional area estimation.
Electron microscopy. For electron microscopy, transversal cross-sections of
70 nm were obtained from the middle part of the muscle-vein-combined
graft, using an Ultracut UCT ultramicrotome (Leica Microsystems).
Sections were then stained with uranyl acetate and lead citrate, and
examined by a JEM-1010 transmission electron microscope (JEOL, Tokyo,
Japan) equipped with a Mega-View-III digital camera and a Soft-Imaging-
System (SIS, Mu¨nster, Germany) for the computerized acquisition of the
images.
Immunofluorescence. For immunofluorescence, tissue were harvested 30
days after main surgery and snap-frozen in liquid nitrogen-cooled
isopentane. Frozen sections (5mm thick) were stained using the following
primary antibodies: anti-slow myosin heavy chain (clone NOQ7.5AD,
Sigma) and anti-laminin (Sigma, Milano, Italy); Alexa488 conjugated goat
anti-rabbit and Alexa594 conjugated donkey anti-mouse (both from
Molecular Probes, Monza, Italy) were used as secondary antibodies.
Images were acquired with a DMLC upright fluorescence microscope (Leica
Microsystems, Milano, Italy) equipped with a charge-coupled device camera
(CoolSNAP CF, Roper Scientific, Roma, Italy) using MetaWiev 4.6 quantitative
analysis software (MDS Analytical Technologies, Sunnyvale, CA, USA). Relative
areas occupied by differently stained cells were quantified by the use of
ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
Results obtained were averaged and expressed as means±s.e.m. Analysis
of variance and Student–Newman–Keuls tests were used to compare data
from different groups.
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